1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
1 citations
,
May 2025 in “Australasian Journal of Dermatology” Caregivers of teens with alopecia areata face significant mental and work-related challenges.
1 citations
,
March 2025 in “Skin Appendage Disorders” Healthcare access for alopecia areata in the USA is unequal among ethnic groups.
1 citations
,
February 2025 in “Medicina” No significant genetic link to alopecia areata was found in the Jordanian group.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
1 citations
,
May 2024 in “Journal of Investigative Dermatology” African American adults and non-White children experience more hair loss episodes than White patients with alopecia areata.
1 citations
,
December 2023 in “International journal of molecular sciences” miR-199a-3p controls hair growth and is linked to alopecia areata.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
1 citations
,
June 2023 in “Genes” Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
1 citations
,
June 2023 in “Dermatology and therapy” People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.
1 citations
,
December 2022 in “Journal of cosmetic dermatology” The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
1 citations
,
October 2022 in “International Journal of Molecular Sciences” Using healthy donor stem cells can potentially calm overactive immune cells and reduce inflammation in severe hair loss patients, offering a possible treatment method.
1 citations
,
January 2021 in “Skin appendage disorders” Alopecia areata in children is usually mild and effectively treated with strong topical steroids.
February 2026 in “Clinical Drug Investigation” Baricitinib significantly improves nail and hair symptoms in severe alopecia areata.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
January 2026 in “Behavioral Sciences” Negative illness perceptions increase emotional distress, worsening OCD symptoms in alopecia areata patients.
Combining systemic steroids and dithranol can effectively regrow hair in severe alopecia areata.
December 2025 in “Cosmetics” Gut bacteria differences could help diagnose and treat alopecia areata.
December 2025 in “Experimental Dermatology” Improving blood vessel health and controlling uric acid may help manage alopecia areata.
November 2025 in “Biomedicines” Targeting pyroptosis may offer new treatments for alopecia areata, but more research is needed.
November 2025 in “Medicina” Alopecia areata may be linked to changes in body fat but not to heart or artery issues.
November 2025 in “Journal of Clinical Medicine” Alopecia areata patients should have eye check-ups due to increased risk of eye problems.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
October 2025 in “Archives of Dermatological Research” Topical metformin gel is as effective and safe as steroids for treating alopecia areata.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.
September 2025 in “Journal of Clinical Medicine” Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.